• news.cision.com/
  • Episurf/
  • Episurf Medical invited to present the Episealer® technology and clinical data at its first US clinical congress

Episurf Medical invited to present the Episealer® technology and clinical data at its first US clinical congress

Report this content

Episurf Medical (Nasdaq: EPIS B) today announces that the company's founder and board member Prof. Leif Ryd will participate in the Orthopaedic Summit 2019: Evolving Techniques, which will take place on December 11-14, 2019 in Las Vegas, Nevada. This event constitutes Episurf Medical's first invitation to a US clinical congress, and Prof. Ryd will actively participate in various clinical sessions. The Orthopaedic Summit is a gathering of Total Joint (Knee, Hip, Shoulder), Foot & Ankle, Sports Medicine, Arthroscopic, Spine and Trauma Surgeons from the global orthopaedic industry. The meeting is expected to host more than 1,000 delegates including medical professionals and industry representatives.

Episurf Medical's founder and Board member, Prof. Leif Ryd, is part of the meeting faculty and is invited to present the Episealer® implant technology.

"This is an important milestone. Never have we been invited to a clinical congress in the US, and this is a large and highly relevant meeting. We are looking forward to having Prof. Ryd there to present the Episealer® technology. We hope to continue to build on the great interest we have experienced from US surgeons concerning our IDE clinical trial," says Pål Ryfors, CEO Episurf Medical. 

"The Orthopaedic Summit 2019: Evolving Techniques meeting in Las Vegas gathers the clinicians of the US, the ones less focused on scientific research, but who are instead focusing on the clinical problems in order to care for their patients. Evolving Techniques suits Episurf perfectly. Our technology is indeed a game-changer, and it will be incredibly exciting to present this technology to a large US audience. These surgeons struggle with the same problem of the GAP-patient - too old for stem cells and biologics, while too young for a knee replacement, as they do in Europe" says Prof. Leif Ryd. 

The Episealer® device is in the US an investigational device, limited by US law to investigational use only. More information to be found at: https://orthosummit.com/.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.